On March 15, 2022, IM Cannabis Corp. ("IM Cannabis") (CSE: IMCC) (NASDAQ: IMCC) announced that it had completed three strategic acquisitions announced in 2021. The acquisitions were completed through IMC Holdings Ltd., a wholly-owned subsidiary of IM Cannabis and I.M.C Pharma Ltd., IMC Holdings' wholly-owned subsidiary, following receipt of all requisite approvals, including from the Israeli Medical Cannabis Unit ("IMCU").
IMC Holdings successfully completed the acquisition of 51% of the outstanding ordinary shares of Revoly Trading and Marketing Ltd., dba Vironna. Vironna ranks among the top 10 single cannabis dispensing points in Israel and is one of the largest pharmacies in Israel serving the rapidly growing Arab consumer segment of the medical cannabis market.
IMC Holdings also completed the acquisition of all the outstanding ordinary shares of R.A. Yarok Pharm Ltd., a leading medical cannabis pharmacy located in central Israel; and Rosen High Way Ltd., a trade and distribution centre with an IMC-GDP license that provides medical cannabis storage, distribution services and logistics solutions for cannabis companies and pharmacies in Israel.
Lastly, IMC Holdings received the requisite IMCU approval to acquire an IMC-GDP license for distribution of medical cannabis from Panaxia Pharmaceutical Industries Israel Ltd. and Panaxia Logistics Ltd., part of the Panaxia Labs Israel, Ltd. group of companies.
IM Cannabis is a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, the three largest federally legal markets.
Gowling WLG was Canadian counsel to IM Cannabis with respect to these acquisitions with a team that included Peter Simeon, Josh Rosen, Jacob Cawker, Cyndi Laval, Josh Almario and Navraj Pannu.
Read the original article on GowlingWLG.com
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
